Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
- 3 July 1997
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (1), 15-21
- https://doi.org/10.1056/nejm199707033370103
Abstract
Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates of cerebrospinal fluid sterilization.This publication has 16 references indexed in Scilit:
- Amphotericin B as Primary Therapy for Cryptococcosis in Patients with AIDS: Reliability of Relatively High Doses Administered over a Relatively Short PeriodClinical Infectious Diseases, 1995
- Fluconazole Combined with Flucytosine for Treatment of Cryptococcal Meningitis in Patients with AIDSClinical Infectious Diseases, 1994
- Cryptococcal Meningitis and AIDSClinical Infectious Diseases, 1993
- Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitisAIDS, 1992
- Best Subsets Logistic RegressionBiometrics, 1989
- Infections withCryptococcus neoformansin the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1989
- Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six WeeksNew England Journal of Medicine, 1987
- A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal MeningitisNew England Journal of Medicine, 1979
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958